Noteworthy

Aug 06, 2017
Female students pursuing a Science, Technology, Engineering, and Mathematics (STEM) pathway need earlier enticement and more C-suite role models, writes Mylan’s Head of Global Commercial Development, Adele Gulfo.
Jul 31, 2017
Time will determine the shape of biosimilar usage in oncology, but they will play a significant role in the battle against cancer in the future, writes Alessandra Franceschetti.
Jul 31, 2017
Internal oversight and the tools to remain compliant are critical to companies seeking to avoid corporate integrity agreements or efficiently fulfill existing agreements, writes Gabriela P. Baron.
Jul 26, 2017
Tensions are becoming clear within industry as it faces what might yet be the toughest negotiations on pricing with the UK government. Leela Barham reports.
Jul 26, 2017
More pharma companies are reporting that their digital strategies are ineffective compared to other industries. Heath Jackson looks at why this is – and what they need to do about it.
Jul 24, 2017
Pharmaceutical Executive
Excitement over more new treatments for cancer and rare diseases is offset by cringing over prices.
Jul 20, 2017
Gregg Fisher reflects on how brand planning can be enhanced to better serve brand and product managers to deliver on the promises of “customer-centric” and “multi-channel” communications.
Jul 19, 2017
Pharmaceutical Executive
Dogs and kids both spontaneously develop a number of cancers, making it a no-brainer for those on both sides of the disease to work together in finding new therapies.
Jul 17, 2017
By Pharmaceutical Executive Editors
The health promises of big data will not be met unless the right technology is put in place to ensure that data can flow freely and fast across a WAN, writes David Trossell.
Jul 17, 2017
Pieter De Richter explores how the molecular diagnostics landscape—and the very way we think about fighting cancer—is set to change dramatically in the coming decades.
native1_300x100
lorem ipsum